Introduction

de Montréal

Faculté de pharmacie

• Prostate cancer is one of the most common cancers in men (22% in 2024)¹ and the fifth leading cause of cancer-related death among men worldwide.²

Université de 100 ans d'excellence

- Since 2015, clinical guidelines have recommended treatment intensification (TI) with androgen deprivation therapy (ADT) plus either Docetaxel or novel hormonal therapies (NHTs) to improve survival outcomes in castration-sensitive prostate cancer (CSPC),³
- These practices have rapidly gained importance in real-world clinical practice
- However, real-world uptake of these therapies and regional variations in practice remain unclear.

Objective

This systematic literature review (SLR) is based on real-world data and aims to summarize and compare real-world treatment patterns for CSPC between 2012 and 2024 across different countries and jurisdictions, with a focus on the adoption of treatment intensification strategies.

• ADT monotherapy o ADT+ TI ○ ADT + other

Methods

- The SLR was conducted using Cochrane dual-reviewer methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol (PRISMA-P) guidelines.⁴
- SLR protocol registered on PROSPERO (ID: CRD42024572896)⁵.
- Database: EMBASE, CINAHL, WOS and MEDLINE.
- Reference snowballing and grey literature searches were conducted.
- Bias management: STROBE checklist ⁶.

Table 1. Eligibility criteria

	Inclusion criteria	Exclusion criteria
Ρ	Men of any age diagnosed with castration-sensitive prostate cancer (CSPC/HSPC)	Diagnosed with castration-resistant prostate cancer (CRPC)
I	 ADT monotherapy ADT + Docetaxel ADT + Apalutamide ADT + Enzalutamide ADT + Abiraterone ± Pred. ADT + Docetaxel + NHT ADT + other 	Data excluding the use of ADT monotherapy or in TI.
С	 Observational studies 	 Systematic literature reviews (SLR Randomized clinical trials (RCTs); Conference abstracts
0	Quantitative expression of usage and prescription trends (percentage, rate, incidence)	 Pharmacoeconomic data exclusively (utility / ICER / ICUR, costs); Efficacy data only (i.e. overall surviv and toxicity
Т	Articles published between 2012 and 2024	Articles published before 2012

Real World Treatment Patterns for Castration-Sensitive Prostate Cancer Between 2012 and 2024: **A Systematic Review**

<u>Meïssa Bougchiche¹, Félix Morin¹, Valentyn Litvin¹, Ivan Yanev^{1,2}, Alice Dragomir^{1,2}</u>

¹University of Montreal, Montreal, Canada; ²McGill University, Montreal, Canada



Faculty of Faculté de Medicine médecine

OT Mono ↑	ADT+Docetaxel ↓	ADT+NHTs ↑
oderate	Sharp decline after 2017	Strong increase 2017
xed	Moderate decline	High in France, Belgium 2019-2020
gh use	Low after 2016	Gradual uptake 2016